Windlas Biotech posts record FY26 revenue of ₹904 crore with 19% YoY growth; CDMO segment up 20%. Adjusted EBITDA₹121 crore (+26%), Adjusted PAT₹83 crore (+31%), net liquidity ₹251 crore and net debt-free.
AI Assistant
Windlas Biotech Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.